BRAF inhibitors tend to trigger paradoxical hyper-activation of pERK and induction of neoplasia in the skin, such as cutaneous squamous cell carcinoma, whereby vemurafenib cause such effects more remarkably than dabrafenib or encorafenib [30]. The gene discussed is BRAF; the disease is cutaneous squamous cell carcinoma.